Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Jul;6(7):682-5.
doi: 10.1631/jzus.2005.B0682.

The treatment of relapsing primary nephrotic syndrome in children

Ya-ping Wang  1 , Ai-min Liu, Yu-wen Dai, Cheng Yang, Hong-feng Tang
Affiliations
Clinical Trial

The treatment of relapsing primary nephrotic syndrome in children

Ya-ping Wang et al. J Zhejiang Univ Sci B. 2005 Jul.

Abstract

Objective: To explore better therapy and reduce the rate of re-relapse of primary nephritic syndrome in children who had been treated with corticosteroids but relapsed.

Methods: Eighty relapsers were enrolled from Jan. 1994 to Apr. 2000, who were randomly divided into two groups. The treatment group (n=39) had been treated with tripterysium glucosides for three months, with the control group (n=41) members were treated with cyclophosphmide (CTX) by intermission intravenous pulse, with total dose of CTX not being more than 150 mg/kg. Prednisone, meanwhile, was given to both groups. The total treatment period of prednisone was prolonged by 12-18 months.

Results: After following up for 3-7 years, the re-relapse rates of both groups were observed. The re-relapse rate of the treatment group was 28.2% to 29.3% in the CTX-controlled group. The re-relapse rates between two groups were almost similar, and with no observed significant difference (P>0.05). The side effect of tripterysium glucosides was less than that of CTX.

Conclusion: For the treatment of relapsing nephritic syndrome in children, the combination of tripterysium glucosides and prolonged corticosteroid therapy is as effective as the regimen of CTX plus prolonged use of prednisone.

PubMed Disclaimer

References

    1. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Arch Dis Child. 2000;83(3):45–51. - PMC - PubMed
    1. Liu D, Yang JW, Chen ZH, Dai CS, Liu ZH, Li LS. Relationship between cell cycle and apoptosis of activated T lymphocyctes induced by triptolide. Chin J Immun. 1999;15(10):455–459.
    1. Mendoia SA, Tune BM. Management of the difficult nephrotic patients. Pediatr-Clin-Am. 1995;42:1459–1468. - PubMed
    1. Qiu D, Kao PN. Immunosupressive and anti-inflammatory mechanisms of triptolide, the principle active diterpenoid from Chinese medicinal herb Tripterygium Wilfordii Hookf. Drugs RD. 2003;4(1):1–18. - PubMed
    1. Takcda A, Takimoto H, Mizusawa Y, Simosa M. Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr-Nephrol. 2001;16:888–893. - PubMed

Publication types

MeSH terms